ITF2357 Interferes with apoptosis and inflammatory pathways in the HL-60 model: A gene expression study

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4525-4535

  Galimberti, Sara ^a   Canestraro, Martina ^a   Savli, Hakan ^b   Palumbo, Giuseppe Alberto ^c   Tibullo, Daniele ^c   Nagy, Balint ^d   Piaggi, Simona ^a   Guerrini, Francesca ^a   Cine, Naci ^b   Metelli, Maria Rita ^e   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b KOCAELI UNIVERSITY   (Turkey)

^c UNIVERSITY OF CATANIA   (Italy)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Apoptosis; Gene expression; Histone deacetylase inhibitor; Inflammation; ITF2357; NF B

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; EPIDERMAL GROWTH FACTOR; FAS LIGAND; GIVINOSTAT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1; RETINOIC ACID RECEPTOR; T LYMPHOCYTE RECEPTOR; TETRAMETHYLRHODAMINE ETHYL ESTER; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CANCER MODEL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NITROBLUE TETRAZOLIUM TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; INFLAMMATION; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78650239591     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hiebert SW, Reed-Inderbitzin EF, Amann J, Irvin B, Durst K and Linggi B: The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14 ARF tumor suppressor. Blood Cells Mol Dis 30: 177-183, 2003. (Pubitemid 36539361)
2. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr. and Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 391: 811-814, 1998. (Pubitemid 28099682)
3. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM and Albagli O: The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 26: 4645-4651, 1998. (Pubitemid 28466611)
4. Mehnert JM and Kelly WK: Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13: 23-29, 2007.
5. Blanchard F and Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197-204, 2005.
6. Fabre C, Grosjean J, Tailler M, Boehrer S, Adès L, Perfettini JL, de Botton S, Fenaux P and Kroemer G: A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 7: 2139-2145, 2008.
7. Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y and Kotani J: Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E 2 secretion in human peripheral blood mononuclear cells. Nutr Res 28: 321-328, 2008.
8. Chavey C, Mühlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, Jobin C and Lazennec G: Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer. Mol Pharmacol 74: 1359-1366, 2008.
9. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA and Mascagni P: The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: 1-15, 2005.
10. Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M and Siegmund B: Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 57: 613-622, 2008.
11. Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M and Rambaldi A: The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 21: 1892-1900, 2007.
12. Birnie GD: The HL60 cell line: a model system for studying human myeloid cell differentiation. Br J Cancer Suppl 9: 41-45, 1998.
13. Testi R, Mattii L, Di Simone D, Zaccaro L, Malvaldi G, Grassi B and Petrini M: Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk Res 19: 257-261, 1995.
14. Andrews NC and Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499-2504, 1991.
15. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A and Petrini M: PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32: 103-112, 2008.
16. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005.
17. Inoue S, Riley J, Gant TW, Dyer MJ and Cohen GM: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21: 1773-1782, 2007. (Pubitemid 47086766)
18. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M and Amadori S: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101: 2125-2131, 2003.
19. Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281: 5612-5622, 2006. (Pubitemid 43847658)
20. Pei XY, Dai Y and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852, 2004. (Pubitemid 38697620)
21. Imre G, Gekeler V, Leja A, Beckers T and Boehm M: Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 66: 5409-5418, 2006. (Pubitemid 43844968)
22. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B and Deeg HJ: NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106: 3917-3925, 2005.
23. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, Introna M, Barbui T, Golay J and Rambaldi A: The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2 (V617F). Leukemia 22: 740-747, 2008.
24. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP and Young BD: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175, 2003. (Pubitemid 36555877)
25. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M: Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217, 2005.
26. Yasui H, Hideshima T, Richardson PG and Anderson KC: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Hematol 132: 385-397, 2006. (Pubitemid 43381614)
27. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA and Ferrara JL: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101: 3921-3926, 2004.
28. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F and Saglio G: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Hematologica 93: 921-924, 2008.
29. Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A, Simeone E, Pipan C, Saglio G and Fanin R: Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Hematol 82: 61-68, 2009.
30. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F and Petrini M: Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Hematol 72: 45-51, 2004. (Pubitemid 38161111)